About Mersana
Mersana is a company based in Cambridge (United States) founded in 2001 was acquired by Day One in November 2025. Mersana has raised $136.23 million across 9 funding rounds from investors including Day One, Takeda Pharmaceuticals and 180 Degree Capital. The company has 102 employees as of December 31, 2024. Mersana offers products and services including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056. Mersana operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 102 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mersana Therapeutics, Inc.
-
Annual Revenue
$40.5 M (USD)9.88as on Dec 31, 2024
-
Net Profit
-$69.19 M (USD)59.69as on Dec 31, 2024
-
EBITDA
-$71.71 M (USD)57.68as on Dec 31, 2024
-
Total Equity Funding
$136.23 M (USD)
in 9 rounds
-
Latest Funding Round
$33.1 M (USD), Series C
Jun 16, 2016
-
Investors
Day One
& 11 more
-
Employee Count
102
as on Dec 31, 2024
-
Acquired by
Day One
(Nov 13, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mersana
Mersana is a publicly listed company on the NASDAQ with ticker symbol MRSN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mersana
Mersana offers a comprehensive portfolio of products and services, including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056.
Platform for developing cytotoxic antibody-drug conjugates for cancer.
Platform for creating immunostimulatory antibody-drug conjugates targeting cancer.
Antibody-drug conjugate in development for cancer treatment applications.
Experimental ADC aimed at improving cancer therapy outcomes.
People of Mersana
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
11 people
Product Management Team
6 people
Scientific Team
4 people
Finance and Accounting
4 people
Legal and Compliance
3 people
Human Resources and Administration
3 people
Head Team
2 people
Unlock access to complete
Funding Insights of Mersana
Mersana has successfully raised a total of $136.23M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $33.1 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mersana
Mersana has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Day One, Takeda Pharmaceuticals and 180 Degree Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Mersana
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mersana
Investment portfolio details for Mersana
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mersana
Detailed financials for Mersana
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mersana Comparisons
Peer comparison for Mersana
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mersana
Mersana operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Mersana
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mersana
Complete news archive for Mersana
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mersana
Mersana was founded in 2001 and raised its 1st funding round 7 years after it was founded.
Mersana is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mersana is a funded company, having raised a total of $136.23M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Mersana is 102.
Annual revenue of Mersana is $40.5M as on Dec 31, 2024.
Mersana Therapeutics was founded in 2001 in Cambridge, United States, within the biotechnology sector focused on oncology. Antibody-drug conjugates are developed to target cancer cells precisely. A biodegradable polymer platform called Fleximer is employed to build these immunoconjugates, enabling delivery of anti-tumor agents directly to diseased tissues. Operations center on advancing therapies like the lead candidate XMT-1522, which addresses HER2-positive cancers.
Mersana's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Mersana offers Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056.
Yes, Mersana is publicly traded on NASDAQ under the ticker symbol MRSN.
Mersana has 12 investors. Key investors include Day One, Takeda Pharmaceuticals, 180 Degree Capital, ArrowMark Partners, and NEA.
The ticker symbol of Mersana is MRSN on NASDAQ.